PHIO

Phio Pharmaceuticals Corp.

0.92 USD

Last updated Dec 11, 09:53 UTC

Yesterday HIGH

$1.02

Yesterday LOW

$0.88

52w HIGH

$12.27

52w LOW

$0.88

EPS

-1.14

PE

-0.81

Next Earnings

Mar 20, 2024

Overview News Government Trades

Phio Pharmaceuticals Corp. stock is down -14.67% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 11 December’s closed higher than November.

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Camden, United States Of America

Website

phiopharma.com

Benzinga Insights

Wed Oct 11, 2023

12 Health Care Stocks Moving In Wednesday's After-Market Session
Lisa Levin

Wed Oct 11, 2023

Crude Oil Down 2.5%; Silk Road Medical Shares Plummet

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded down 0.01% to 33,736.15 while the NASDAQ rose 0.42% to 13,619.46. The S&P 500 also rose, gaining, 0.14% to 4,364.45.
Vandana Singh

Wed Oct 11, 2023

Why Is Immuno-Oncology Focused Phio Pharmaceuticals Stock Trading Higher Today?

Phio Pharmaceuticals Corp (NASDAQ: PHIO) shares are trading higher after the company announced the poster presentation of two preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular
Benzinga Insights

Wed Oct 11, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Lisa Levin

Wed Oct 11, 2023

Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study.
Lisa Levin

Wed Oct 11, 2023

Dow Turns Lower; Tempest Therapeutics Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Wednesday. The Dow traded down 0.19% to 33,674.66 while the NASDAQ rose 0.18% to 13,586.67. The S&P 500 also rose, gaining, 0.12% to 4,353.19.
Benzinga Insights

Wed Oct 11, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
ryanfaloona@benzinga.com

Wed Oct 11, 2023

Market-Moving News for October 11th

TPST: 440% | Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study PHIO: 77% | Phio Pharmaceuticals Presents New Data
Benzinga Newsdesk

Wed Oct 11, 2023

Phio Pharmaceuticals Announced The Poster Presentation Of Two Key Preclinical Studies Of Its INTASYL Compound PH-894 At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination Preclinical data demonstrates the effectiveness of PH-894 as an antitumor
Benzinga Insights

Tue Oct 3, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session